The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
2013 · British Journal of Cancer · 347 citations
https://doi.org/10.1038/bjc.2013.671
M
Mathias Gehrmann
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
134
Papers
4.1K
Citations
26
h-index
32
i10-index
Mathias Gehrmann is an academic researcher from Siemens Healthineers (Germany). The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Cancer Cells and Metastasis. The author has an h-index of 26, co-authored 114 publications.
ORCID: 0000-0002-1233-0336Papers by this author
worksRole of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer
2010 · Breast Cancer Research · 218 citations
https://doi.org/10.1186/bcr2599
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
2012 · Annals of Oncology · 213 citations
https://doi.org/10.1093/annonc/mds334
Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules
2010 · BMC Cancer · 154 citations
https://doi.org/10.1186/1471-2407-10-604
ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
2010 · Clinical Cancer Research · 132 citations
https://doi.org/10.1158/1078-0432.ccr-09-2471
Integration of pathway knowledge into a reweighted recursive feature elimination approach for risk stratification of cancer patients
2010 · Bioinformatics · 97 citations
https://doi.org/10.1093/bioinformatics/btq345
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat